Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

NCT07691515 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Intrahepatic Cholangiocarcinoma (Icc)

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Tislelizumab
DRUG: Lenvatinib
PROCEDURE: Transcatheter Arterial Chemoembolization
PROCEDURE: Hepatic Arterial Infusion Chemotherapy

Sponsor

Zhejiang Cancer Hospital